Avantor（AVTR）株式概要
は、アメリカ、ヨーロッパ、アジア、中東、アフリカのバイオ医薬品、ヘルスケア、教育、政府機関、先端技術、応用材料業界の顧客にミッションクリティカルな製品とサービスを提供している。 詳細
AVTR Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Avantor, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$7.88 |
| 52週高値 | US$15.93 |
| 52週安値 | US$7.27 |
| ベータ | 0.93 |
| 1ヶ月の変化 | -7.29% |
| 3ヶ月変化 | -14.44% |
| 1年変化 | -37.21% |
| 3年間の変化 | -61.39% |
| 5年間の変化 | -75.06% |
| IPOからの変化 | -45.66% |
最新ニュース
ナラティブの更新 • May 01
AVTR: Reset Expectations And Execution Progress May Support Future Upside
Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.Seeking Alpha • Apr 30
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking AlphaRecent updates
ナラティブの更新 • May 01
AVTR: Reset Expectations And Execution Progress May Support Future Upside
Avantor's updated analyst price target moves lower by several dollars to reflect a reset in fair value to $9.92, as analysts reference reduced price targets across the Street and ongoing questions around market share trends and management execution. Analyst Commentary Recent Street research around Avantor clusters around lower price targets and a downgrade in rating, with most comments focused on valuation reset, market share questions, and confidence in management execution.Seeking Alpha • Apr 30
Avantor Q1 2026 Earnings Review: Stabilization Emerging, But Recovery Not Yet Visible
Summary Avantor, Inc. reported a slight beat on 1Q26 EPS and revenue, but underlying organic growth and margins remain under pressure. Negative organic growth, margin compression, and subdued cash flow signal only early stabilization, not a confirmed recovery, especially in the VWR segment. Management reaffirmed 2026 guidance and expects sequential improvement, but the recovery is execution-dependent and gradual, with margins likely to remain below historical peaks. Valuation screens as discounted, but low multiples reflect market skepticism about AVTR’s growth durability and margin structure; a hold rating is maintained pending clearer evidence of turnaround. Read the full article on Seeking Alpha
ナラティブの更新 • Apr 16
AVTR: Expanded Quality Control Capabilities Will Support Execution Turnaround And Future Share Repricing
Analysts have trimmed their average price targets on Avantor, and the updated fair value estimate now stands at about $16.47. This reflects a softer sentiment around the stock as research notes point to share losses, reduced investment, and questions about management's ability to stabilize the business.ナラティブの更新 • Apr 02
AVTR: Reset Expectations And Share Repurchases May Support Future Upside
The analyst price target for Avantor has shifted lower to reflect a series of Street target cuts, including a move to $8.50. This change stems from concerns about share losses, constrained investment, and uncertainty over whether management can stabilize the business.ナラティブの更新 • Mar 19
AVTR: Execution Turnaround In Core Franchise Will Drive Future Share Repricing
Analysts have lowered their price targets on Avantor, with the updated fair value estimate moving from about $17.68 to $16.13 as they factor in concerns about share losses, underinvestment, and uncertainty around management's ability to stabilize the business, along with a higher assumed discount rate and P/E multiple. Analyst Commentary Recent Street research has tilted cautious on Avantor, highlighted by a downgrade to Underweight with a US$8.50 price target and several cuts to prior price targets.ナラティブの更新 • Mar 05
AVTR: Reset Expectations And Buybacks Will Support Future Upside Potential
Analysts have cut their average price target on Avantor by a few dollars to reflect lower fair value estimates, softer assumed revenue growth and profit margins, and a higher future P/E multiple in light of recent broad target reductions from firms across the Street. Several have moved targets in a $2 to $4 range, and one reset its view from $14 to $12.分析記事 • Feb 13
The Market Doesn't Like What It Sees From Avantor, Inc.'s (NYSE:AVTR) Revenues Yet As Shares Tumble 27%
Avantor, Inc. ( NYSE:AVTR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...ナラティブの更新 • Feb 04
AVTR: Service Expansion And Execution Will Drive Upside From Reset Expectations
Narrative Update: Avantor Analyst Price Target Shift Analysts recently trimmed their price target on Avantor to $12 from $14. This reflects updated views on the life science tools sector and a Q4 outlook where many companies have already set softer expectations for 2026.ナラティブの更新 • Jan 21
AVTR: Share Repurchases And Execution Risks Will Shape Turnaround Visibility
Analysts have trimmed their price target on Avantor by about $0.60, reflecting more cautious assumptions on revenue growth and future P/E. This is partly offset by slightly higher profit margin expectations and a marginally lower discount rate.ナラティブの更新 • Jan 07
AVTR: Execution Turnaround And Review Process Will Unlock Share Repricing Potential
Avantor's analyst price targets and fair value estimates have inched higher to around $17.68 per share. At the same time, lower assumed revenue growth, a higher discount rate, a reduced future P/E, and sharply higher profit margin expectations reflect analysts' mixed views following recent downgrades and concerns about execution and visibility.ナラティブの更新 • Dec 14
AVTR: Share Repurchases Will Drive Upside As Turnaround Visibility Improves
Analysts have modestly lowered their price targets on Avantor by a few dollars per share, generally to the low to mid teens in dollar terms. They cite reduced guidance, weaker quarters and limited visibility around the company’s turnaround and strategic review.ナラティブの更新 • Nov 28
AVTR: Share Repurchase Initiative And Execution Will Shape Recovery Prospects Ahead
Analysts have lowered their price target for Avantor from $14 to $12 per share, citing a weak quarter, reduced guidance, and ongoing execution risks as primary concerns behind the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets ahead of quarterly results, reflecting improved confidence in Avantor’s long-term positioning despite current volatility.ナラティブの更新 • Nov 14
AVTR: Share Repurchase And Execution Will Define Turnaround Prospects In 2025
Avantor’s analyst price target has decreased from $13.80 to $13.64. Analysts cite reduced company guidance, execution risks, and ongoing uncertainty surrounding its earnings outlook as key factors driving the revision.分析記事 • Nov 01
Avantor, Inc. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
There's been a major selloff in Avantor, Inc. ( NYSE:AVTR ) shares in the week since it released its third-quarter...ナラティブの更新 • Oct 31
AVTR: Activist Pressure And Business Overhaul Will Drive Share Recovery
Avantor’s analyst price target has been reduced from $14.40 to $13.80 per share, as analysts cite ongoing operational headwinds and limited near-term earnings visibility following recent downgrades and mixed guidance. Analyst Commentary Recent analyst notes on Avantor capture a divided outlook, reflecting both positive updates from some firms and notable caution from others as the company contends with ongoing operational challenges.分析記事 • Oct 28
There's No Escaping Avantor, Inc.'s (NYSE:AVTR) Muted Earnings Despite A 28% Share Price Rise
Avantor, Inc. ( NYSE:AVTR ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...ナラティブの更新 • Oct 16
Pharma Contracts And R&D Will Drive Growth Amid Price Pressures
Analysts have modestly increased their price target for Avantor, raising it by $0.28 to $14.40. They cite revised expectations for end market recovery and alignment with company outlooks.分析記事 • Sep 12
We Think Avantor (NYSE:AVTR) Is Taking Some Risk With Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...分析記事 • Aug 12
Concerns Surrounding Avantor's (NYSE:AVTR) Performance
NYSE:AVTR 1 Year Share Price vs Fair Value Explore Avantor's Fair Values from the Community and select yours Avantor...分析記事 • Jun 26
What Is Avantor, Inc.'s (NYSE:AVTR) Share Price Doing?
Avantor, Inc. ( NYSE:AVTR ), might not be a large cap stock, but it saw a double-digit share price rise of over 10% in...Seeking Alpha • Apr 26
Avantor: A Healthier Diagnosis As Expectations Cool
Summary Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio. The risk-reward profile has improved due to lower expectations, but the outlook remains cautious amidst continued sales declines and pending leadership changes. Read the full article on Seeking AlphaSeeking Alpha • Mar 07
Avantor: Mundane Business, Solid Cash Flow, Potential New Risks
Summary Avantor, Inc. has seen a significant decline in its stock price recently. The company did divest itself of one business this summer, paying down some debt with the proceeds. In addition, the company delivered an impressive amount of free cash flow in FY2024. Buy, Sell or Hold? An analysis around AVTR stock follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Avantor: Durable FCF Generator Trading For Cheap
Summary Avantor's robust business model yields stable cash flows and generates sticky customers. Avantor’s leadership in the biopharma industry and shifting revenue mix can produce considerable margin expansion. Significant FCF generation can improve the company’s capital structure and return value to shareholders. Potential industry inflection point creates optimal entry point with multiple expansion. Read the full article on Seeking AlphaSeeking Alpha • Oct 24
Avantor: Uninspiring, Even Amidst Some Green Shoots
Summary Avantor shares have struggled on the back of a high valuation, significant debt, and lackluster growth, despite recent improvements in organic sales and a divestment. The company operates two segments: a $4.7 billion laboratory solutions business, and a $2.2 billion bioscience production business, with the latter having higher margins. Recent financials show declining sales and earnings, amidst high valuation and a demanding valuation. A $650 million divestment aims to reduce debt, but the overall risk-reward remains unattractive given the company's past performance and high leverage. Read the full article on Seeking Alpha
新しいナラティブ • Aug 21
New Operating Model And Bioprocessing Innovations Promise Robust Growth And Market Leadership
Implementation of a new operating model and ongoing cost transformation initiatives are streamlining execution and improving net margins through cost savings.Seeking Alpha • Aug 13
Avantor: Yet To Evidence Economic Value For Valuation Repricing, Reiterate Hold
Summary AVTR stock is up 18% post Q2 FY'24 earnings, but momentum and quality continue to diverge. The company's balance sheet is saddled with debt, whilst earnings produced on capital are flattening. Valuations are unsupportive at >35x earnings, and I continue to rate AVTR a hold with little headroom for upside under present conditions. Read the full article on Seeking Alpha株主還元
| AVTR | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 0.1% | 1.6% | -0.3% |
| 1Y | -37.2% | 7.1% | 26.7% |
業界別リターン: AVTR過去 1 年間で7.1 % の収益を上げたUS Life Sciences業界を下回りました。
リターン対市場: AVTRは、過去 1 年間で26.7 % のリターンを上げたUS市場を下回りました。
価格変動
| AVTR volatility | |
|---|---|
| AVTR Average Weekly Movement | 5.1% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: AVTR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: AVTRの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1904 | 13,500 | Emmanuel Ligner | www.avantorsciences.com |
は、アメリカ、ヨーロッパ、アジア、中東、アフリカのバイオ医薬品、ヘルスケア、教育、政府機関、先端技術、応用材料業界の顧客にミッションクリティカルな製品とサービスを提供しています。純度の高い化学薬品や試薬、研究用製品や消耗品、調合されたシリコーン材料、カスタマイズされた賦形剤、カスタマイズされたシングルユースアセンブリー、プロセスクロマトグラフィー用樹脂やカラム、分析用サンプル前処理キット、教育および微生物学製品、臨床試験キット、流体処理用チップなどの材料や消耗品を提供している。また、ろ過システム、ウイルス不活性化システム、インキュベーター、分析機器、エバポレーター、超低温フリーザー、生物学的安全キャビネット、ペリスタポンプ、クリティカル環境用品などの機器・装置製品も提供している。加えて、同社はオンサイトラボや製造、機器、調達とソーシング、バイオ医薬品材料のスケールアップと開発サービスからなるサービスと特殊な調達を提供している。さらに、DNA抽出、バイオリアクターサービス、臨床・バイオ保管、化合物管理、クリーンルーム管理、モニタリング、メンテナンス、除菌サービスなどの科学研究支援サービスも提供している。同社は1904年に設立され、ペンシルベニア州ラドナーに本社を置いている。
Avantor, Inc. 基礎のまとめ
| AVTR 基礎統計学 | |
|---|---|
| 時価総額 | US$5.22b |
| 収益（TTM） | -US$551.40m |
| 売上高(TTM) | US$6.55b |
0.8x
P/Sレシオ-9.8x
PER（株価収益率AVTR は割高か？
公正価値と評価分析を参照収益と収入
| AVTR 損益計算書（TTM） | |
|---|---|
| 収益 | US$6.55b |
| 売上原価 | US$4.45b |
| 売上総利益 | US$2.11b |
| その他の費用 | US$2.66b |
| 収益 | -US$551.40m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.81 |
| グロス・マージン | 32.13% |
| 純利益率 | -8.42% |
| 有利子負債／自己資本比率 | 67.8% |
AVTR の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 09:38 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Avantor, Inc. 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29
| アナリスト | 機関 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |